alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

27,780 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 1–22 of 22 studies in Treatments published 2002 · 27,780 in the whole library · How the 0–100 score works

Download bibliography of these 22 studies, in this order: BibTeX (.bib) · RIS (.ris)

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Other subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Institutions

From OpenAlex; 13,259 studies have no institution on record and are not counted here.

What “Treatments” covers

Treatments — Drug and non-drug treatment research — what was tested, in whom, and what changed — plus the approvals and coverage decisions that followed.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) study

✓ Peer-reviewed alzhub usefulness score 75 out of 100. Archives of internal medicine 2002-10-01

Median follow-up increased from 2.0 years in the double-blind trial to 3.9 years overall. 2 key findings →

Participants: 1,485 Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial

✓ Peer-reviewed alzhub usefulness score 73 out of 100. Lancet (London, England) 2002-04-01

Vascular dementia is the second commonest form of dementia, and vascular factors contribute to the development of dementia in many patients with Alzheimer's disease. 5 key findings →

Participants: 396 Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300)

✓ Peer-reviewed alzhub usefulness score 65 out of 100. Stroke 2002-07-01

Based on the hypothesis of glutamate-induced neurotoxicity (excitotoxicity) in cerebral ischemia, this study examined the efficacy and tolerability of memantine, an uncompetitive N-methyl-D-aspartate antagonist, in the treatment of mild to moderate vascular dementia. 4 key findings →

Participants: 321 Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

A double-blind, placebo-controlled multicentre study of memantine in mild to moderate vascular dementia (MMM500)

✓ Peer-reviewed alzhub usefulness score 65 out of 100. International clinical psychopharmacology 2002-11-01

The aim of the reported trial was to investigate the safety and efficacy of memantine in mild to moderate vascular dementia (VaD). 4 key findings →

Design: randomized controlled trial Participants: 579 Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

[Clinical efficacy and safety of huperzine Alpha in treatment of mild to moderate Alzheimer disease, a placebo-controlled, double-blind, randomized trial]

✓ Peer-reviewed alzhub usefulness score 58 out of 100. Zhonghua yi xue za zhi 2002-07-01

A safe and effective medicine, huperzine Alpha remarkably improves the cognition, behavior, ADL,and mood of AD patients. 2 key findings →

Participants: 100 Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

The effects of a walking/talking program on communication, ambulation, and functional status in residents with Alzheimer disease

✓ Peer-reviewed alzhub usefulness score 56 out of 100. Alzheimer disease and associated disorders 2002-04-01

The purpose of this study was to investigate the effects of a walking/talking program on residents' communication, ambulation, and level of function when there were two residents to one care provider (2:1). 2 key findings →

Evidence: high

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Snoezelen for dementia

✓ Peer-reviewed alzhub usefulness score 55 out of 100. The Cochrane database of systematic reviews 2002-01-01

Practitioners are keen to use snoezelen in dementia care, and some encouraging results have been documented in the area of promoting adaptive behaviours (e.g. The list of trials was compared with those identified from a search of the Specialized Register of the Cochrane Dementia and Cognitive Improvement Group. 5 key findings →

Design: systematic review Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

HMG-CoA reductase inhibitors (statins) in the treatment of Alzheimer's disease and why it would be ill-advise to use one that crosses the blood-brain barrier

✓ Peer-reviewed alzhub usefulness score 55 out of 100. The journal of nutrition, health & aging 2002-01-01

Increased circulating cholesterol has been long linked to an increased risk of coronary artery disease (CAD), and is now linked to an increased risk of developing Alzheimer s disease (AD). 3 key findings →

Evidence: high

Full summary, score breakdown and related studies → Original source Full text may need a subscription

H2 histamine receptor blockade in the treatment of Alzheimer disease: a randomized, double-blind, placebo-controlled trial of nizatidine

✓ Peer-reviewed alzhub usefulness score 55 out of 100. Alzheimer disease and associated disorders 2002-01-01

These results do not support claims for the efficacy of nizatidine in over-the-counter dosages as a means of preventing symptom progression in AD. 2 key findings →

Evidence: high

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Cholinesterase inhibitor treatment alters the natural history of Alzheimer's disease

✓ Peer-reviewed alzhub usefulness score 50 out of 100. Journal of neurology, neurosurgery, and psychiatry 2002-03-01

The short and long term effects of CEIs were evaluated in 135 patients with probable Alzheimer's disease relative to 135 patients who were never exposed to CEIs matched by age, education, duration of the symptoms, and cognitive status. 4 key findings →

Participants: 135 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Galantamine--a novel cholinergic drug with a unique dual mode of action for the treatment of patients with Alzheimer's disease

✓ Peer-reviewed alzhub usefulness score 44 out of 100. CNS drug reviews 2002-01-01

It is extensively metabolized in numerous pathways, mainly in the liver via cytochrome P450 enzymes CYP2D6 and CYP3A4, and has a low potential for clinically significant drug-drug interactions. 5 key findings →

Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

Molecular targeting of Alzheimer's amyloid plaques for contrast-enhanced magnetic resonance imaging

✓ Peer-reviewed alzhub usefulness score 36 out of 100. Neurobiology of disease 2002-11-01

Smart molecular probes for both diagnostic and therapeutic purposes are expected to provide significant advances in clinical medicine and biomedical research. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 27,780 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,780 records, built mostly from automated pulls of Europe PMC (61.1% of the library) and OpenAlex (18.3%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed